Clinical trial
Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C
NCT00336479 · Vertex Pharmaceuticals Incorporated, Industry · Completed
Key facts
| NCT number | NCT00336479 |
|---|---|
| Title | Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C |
| Official title | A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With Ribavirin (Copegus®) in Subjects With Genotype 1 Hepatitis C Who Have Not Received Prior Treatment |
| Lead sponsor | Vertex Pharmaceuticals Incorporated, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C |
| Intervention type | Drug, Other |
| Interventions | Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo |
| Enrollment | 263 |
| Start date | Jun 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Jun 13, 2006 |
| Last update posted | Jul 23, 2014 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: